Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis

Sun, Jian; Kong, Chen-Fan; Qu, Xiang-Ke; Deng, Chao; Lou, Yanni; Jia, Liqun

doi:10.4103/sjg.sjg_384_19

Cited by 23 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, another six studies (30%) reported promising results in the control of immune and inflammatory responses, as well as other side effects related to their overall well-being and daily life activities. These findings further support the idea of previous reviews [44,45], suggesting that microbiota plays a key role in the pathogenesis of some treatment-related side effects, although further evidence is needed to determine their safety and accuracy [46,47].…”

Section: Discussionsupporting

confidence: 88%

Probiotic Supplements on Oncology Patients’ Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials

Rodriguez‐Arrastia

Martinez-Ortigosa

Rueda‐Ruzafa

et al. 2021

IJERPH

View full text Add to dashboard Cite

Cancer affects more than 19.3 million people and has become the second leading cause of death worldwide. Chemo- and radiotherapy, the most common procedures in these patients, often produce unpleasant treatment-related side effects that have a direct impact on the quality of life of these patients. However, innovative therapeutic strategies such as probiotics are being implemented to manage these complications. Thus, this study aimed to evaluate the efficacy of probiotics supplements as a therapeutic strategy in adult oncology treatment-related side effects. A systematic review of randomized controlled trials was conducted in PubMed, Scielo, ProQuest and OVID databases up to and including January 2021, following the PRISMA guidelines. The quality of the included studies was assessed by the Jadad Scale. Twenty clinical trials published between 1988 and 2020 were included in this review. Seventeen studies (85%) revealed predominantly positive results when using probiotics to reduce the incidence of treatment-related side effects in oncology patients, while three studies (15%) reported no impact in their findings. This study sheds some light on the significance of chemotherapy and radiotherapy in altering the composition of gut microbiota, where probiotic strains may play an important role in preventing or mitigating treatment-related side effects.

show abstract

Section: Discussionsupporting

confidence: 88%

Probiotic Supplements on Oncology Patients’ Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials

Rodriguez‐Arrastia

Martinez-Ortigosa

Rueda‐Ruzafa

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Estudo feito por Mezzasalma et al 2016 A partir da leitura criteriosa dos textos selecionados, foi possível observar que os estudos são heterogêneos no que concerne ao uso de probióticos para alívio sintomático da SII, sendo inconclusivo quanto a sua eficácia e segurança, já que, com base no que sugere Ooi et al (2019), as evidências atuais de revisões sistemáticas e metanálises apoiam, em definitivo, a adoção de probióticos. Em contrapartida, conforme Sun et al (2019), é difícil tirar conclusões definitivas sobre a terapêutica, uma vez que não está claro como os probióticos podem aliviar os sintomas da SII, evidenciando a falta de consenso entre um artigo e outro.…”

Section: Resultsunclassified

“…Durante a Conferência de Roma IV foi estabelecido que o diagnóstico da SII pode ser feito quando o paciente apresenta queixa de dor abdominal recorrente associada a pelo menos dois outros sintomas como dor à defecação, mudança na frequência das fezes e alteração na aparência dos dejetos (PRINCIPI et al, 2017). Conforme os critérios de Roma IV, a SII pode ser dividida em quatro tipos de acordo com os sintomas apresentados, sendo IBS-C (irritable bowel syndrom-C) quando há constipação, IBS-D na presença de diarreia, quando apresenta ambos os sintomas, é classificado como IBS-M e, já quando não é classificado, tem-se o IBS-U, em que não apresenta nenhum dos sintomas anteriores (SUN et al, 2019).…”

Section: Discussionunclassified

Uso de probióticos no tratamento de pacientes com síndrome do intestino irritável

Costa

Almeida

Silveira

et al. 2020

BJHR

View full text Add to dashboard Cite

“…In addition, Bifidobacterium infantis Y1 and Bifidobacterium breve Y8 ameliorated the clinical symptoms and changed the diversity and composition of the gut microbiota in chronic diarrhea patients (9). Probiotics, including Lactobacillus and Bifidobacterium, were favored over placebo for their effects on the overall symptoms of IBS (10,11). However, some studies have reported contrasting effects, which may be related to strain-specific properties and a change in the host itself (12).…”

Section: Introductionmentioning

confidence: 99%

Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study

et al. 2021

View full text Add to dashboard Cite

Irritable bowel syndrome with diarrhea and functional diarrhea are both functional bowel disorders that cause chronic diarrhea. Chronic diarrhea is closely related to daily life and the psychological condition of diarrhea in patients, and probiotics can play a significant role in alleviating chronic diarrhea in some research. Lactobaccilus plantarum CCFM1143 can relieve diarrhea in mice caused by enterotoxigenic Escherichia coli (ETEC); however, its clinical effects remain unclear. This study aimed to assess the effects of CCFM1143 as a therapy for chronic diarrhea patients. Fifty-five patients with chronic diarrhea were randomly assigned into the probiotic group (n = 28) and the placebo group (n = 27), receiving the routine regimen with or without probiotics for 4 weeks, respectively. CCFM1143 can mitigate the apparent clinical symptoms and improve the health status and quality of life of patients. In addition, it could inhibit the increase in interleukin 6 (IL-6) and the decrease in motilin; modulate the short-chain fatty acids, especially acetic and propionic acids; and regulate the gut microbiota, particularly reducing the abundance of Bacteroides and Eggerthella and enriching the abundance of Akkermansia, Anaerostipes, and Terrisporobacter. In addition, treatment with probiotics showed clinical effectiveness in managing chronic diarrhea when compared with the placebo group. The findings could help to develop and further the application of probiotics for chronic diarrhea.

show abstract

Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis

Cited by 23 publications

References 54 publications

Probiotic Supplements on Oncology Patients’ Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials

Probiotic Supplements on Oncology Patients’ Treatment-Related Side Effects: A Systematic Review of Randomized Controlled Trials

Uso de probióticos no tratamento de pacientes com síndrome do intestino irritável

Lactobacillus plantarum CCFM1143 Alleviates Chronic Diarrhea via Inflammation Regulation and Gut Microbiota Modulation: A Double-Blind, Randomized, Placebo-Controlled Study

Contact Info

Product

Resources

About